TuHURA Biosciences’ (HURA) Buy Rating Reaffirmed at HC Wainwright

Posted by Lauren Steadman on May 16th, 2025

TuHURA Biosciences (NASDAQ:HURA – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $12.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 212.50% from the company’s current price.

TuHURA Biosciences Stock Performance

HURA stock opened at $3.84 on Friday. The firm has a 50-day moving average price of $3.65. TuHURA Biosciences has a fifty-two week low of $1.80 and a fifty-two week high of $7.93.

TuHURA Biosciences (NASDAQ:HURA – Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02).

Institutional Trading of TuHURA Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of HURA. Apollon Wealth Management LLC purchased a new stake in TuHURA Biosciences in the 4th quarter worth approximately $253,000. Suncoast Equity Management bought a new position in shares of TuHURA Biosciences in the fourth quarter worth approximately $421,000. Charles Schwab Investment Management Inc. bought a new position in shares of TuHURA Biosciences in the fourth quarter worth approximately $61,000. Accent Capital Management LLC purchased a new stake in shares of TuHURA Biosciences in the fourth quarter worth $29,000. Finally, Geode Capital Management LLC bought a new stake in shares of TuHURA Biosciences during the 4th quarter valued at $1,084,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

(Get Free Report)

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.